AndrewFrazierShorrMD
Pulmonology • Washington, DCCritical Care Medicine, Pleural Disease
Associate Professor, Medicine, Georgetown University School of Medicine
Dr. Shorr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St NW
# 2A38
Washington, DC 20010Phone+1 202-877-2848Fax+1 202-877-6292
Education & Training
National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000- National Capital ConsortiumResidency, Internal Medicine, 1994 - 1997
University of Virginia School of MedicineClass of 1995
Certifications & Licensure
MD State Medical License 2000 - 2025
DC State Medical License 2005 - 2024
PA State Medical License 1997 - 2000
VA State Medical License 1996 - 2000- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Start of enrollment: 2009 Aug 01
- Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 90 citationsContinuous Subglottic Suctioning for the Prevention of Ventilator-Associated Pneumonia: Potential Economic ImplicationsAndrew F. Shorr, Patrick G. O’Malley
Chest. 2001-01-01 - 12 citationsMultiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013–2018: a retrospective cohort studyMarya D. Zilberberg, Brian H. Nathanson, Kate Sulham, Andrew F. Shorr
BMC Infectious Diseases. 2021-02-08 - 391 citationsLinezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.Richard G. Wunderink, Michael S. Niederman, Marin H. Kollef, Andrew F. Shorr, Mark J. Kunkel
Clinical Infectious Diseases. 2012-03-01
Press Mentions
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (Sulbactam for Injection; Durlobactam for Injection), Co-Packaged for Intravenous UseMay 23rd, 2023- FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICUDecember 6th, 2022
- Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe PneumoniaAugust 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
